Press Detail

/

PRESS RELEASE

Biotest AG opens fourth plasma collection centre in Hungary

- Twelve plasma collection centres in Europe and

- Eighteen in the US to ensure long-term plasma supply

Dreieich, 7 April 2016. Yesterday, Biotest received an operating permit for its fourth plasma collection centre in Hungary from the country's pharmaceutical regulatory authority, OGYÉI. The centre is in the western Hungarian city of Györ and is one of Europe's most modern. It has 750 square metres and space for up to 35 donation chairs. Thus, the company is further expanding its plasma collection capacity and is adjusting the plasma supply to future growth.

The first plasma collection centre in Budapest was opened by Plazmaszolgálat Kft., a 100% subsidiary of Biotest AG, in 2009. "We are very pleased about the opening of another donor centre in Hungary. Hungary is an ideal location for us with our subsidiary Biotest Hungaria Kft., founded more than 25 years ago, and also due to the good infrastructure and excellent educational level, particularly in the medical field", emphasized Dr Bernhard Ehmer, CEO of Biotest AG.

The collected plasma is processed only by Biotest AG in Dreieich. By expanding its plasma collection capacity, the company is able to supply the Hungarian market with products exclusively from Hungarian plasma. Regular audits ensure that the strict legal and internal quality requirements are met.

About human blood plasma
Human blood plasma is a raw material used to produce plasma derived products, which are used to treat various illnesses of the immune system, the blood system, as well as in emergency medicine. Biotest ranks as one of the world's sixth largest plasma protein product manufacturing groups. Biotest is one of the world's six largest manufacturers of plasma protein products.

About Biotest
Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. In addition Biotest develops monoclonal antibodies in the indications of cancer of plasma cells and systemic lupus erythematosus which are produced by recombinant technologies. Biotest has more than 2,200 employees worldwide. The preference shares of Biotest AG are listed in the SDAX on the Frankfurt stock exchange.

IR contact
Dr. Monika Buttkereit
phone: +49-6103-801-4406
email: investor_relations@biotest.de

PR contact
Dirk Neumüller
phone: +49-6103-801-269
email: pr@biotest.de

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, www.biotest.de

Ordinary shares: securities' ID No. 522720; ISIN DE0005227201
Preference shares: securities' ID No. 522723; ISIN DE0005227235
Listing: Prime Standard
Open Market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hannover, Munich, Stuttgart

Disclaimer

This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.